[Effectiveness of a new Soviet drug Benzonal, inductor of microsomal enzymes of the liver, in the complex treatment of hemolytic disease of newborn].
The effects of benzonal on the course of neonatal hemolytic disease due to the Rhesus factor-conflict was studied in comparison with that of phenobarbital. Dynamic follow-up of infants in the early neonatal period showed benzonal to produce a more pronounced hypobilirubinemic effect which was manifested as a prompter disappearance of skin jaundice and lower percentages of complications. By depressing the activity of organospecific enzymes and lowering the serum biliary acid levels, benzonal promotes normalization of the metabolic shifts present in neonatal hemolytic disease. The findings make it possible to recommend the new inductor of microsomal liver enzymes benzonal as part of the combined therapy of neonatal hemolytic disease.